Key result
Therapeutic angiogenesis for cardiovascular disease has failed to translate promising animal model results into meaningful clinical results in numerous randomized control trials.
Why the study?
Promising animal results with angiogenesis promotors for peripheral vascular disease and coronary artery disease failed to translate into meaningful clinical results in randomized controlled trials.
Despite promising preclinical data, therapeutic angiogenesis has failed to demonstrate meaningful clinical benefits in randomized trials for cardiovascular disease.
Therapeutic angiogenesis should not yet change practice; leaves open refined strategies after repeated RCT failures.
After the success of novel angiogenesis inhibitors in cancer treatment, angiogenesis promotors for the treatment of peripheral vascular disease and coronary artery disease became the target of significant research. Promising results in animal models led to numerous randomized control trials that failed to translate into meaningful clinical results. The goal of this review is to describe the history of investigation into therapeutic angiogenesis for cardiovascular disease and discuss the lessons learned and future directions.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2024) conducted a review in Cardiovascular disease (peripheral vascular disease and coronary artery disease). Therapeutic angiogenesis was evaluated. Therapeutic angiogenesis for cardiovascular disease has failed to translate promising animal model results into meaningful clinical results in numerous randomized control trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: